OAG 83-333 is cited in the decision to provide a foundational legal basis regarding the misbranding of drugs as outlined in KRS 217.065(1), which states that a drug or device is deemed misbranded if its labeling is false or misleading in any particular. This previous opinion is used to support the current opinion that drugs marked as 'sample,' 'not for sale,' or similar wording are misbranded when sold or offered for sale, as this contradicts the labeling.
OAG 83-333 was Followed by OAG 83-452
Our AG treatments are described and categorized by large language models (AI) and are partially reviewed by Coalition directors. Learn more from our blog.
Disclaimer:
The Sunshine Law Library is not exhaustive and may contain errors from source documents or the import process. Nothing on this website should be taken as legal advice. It is always best to consult with primary sources and appropriate counsel before taking any action.
The Sunshine Law Library is not exhaustive and may contain errors from source documents or the import process. Nothing on this website should be taken as legal advice. It is always best to consult with primary sources and appropriate counsel before taking any action.